Old West Investment Management LLC Raises Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Old West Investment Management LLC grew its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 11.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 380,240 shares of the biopharmaceutical company's stock after buying an additional 39,799 shares during the quarter. Amicus Therapeutics accounts for approximately 1.5% of Old West Investment Management LLC's holdings, making the stock its 23rd biggest holding. Old West Investment Management LLC owned approximately 0.13% of Amicus Therapeutics worth $3,582,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in FOLD. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Amicus Therapeutics during the third quarter valued at approximately $55,000. R Squared Ltd purchased a new stake in Amicus Therapeutics during the 4th quarter valued at $79,000. Virtu Financial LLC bought a new stake in Amicus Therapeutics in the third quarter worth $107,000. KBC Group NV boosted its stake in Amicus Therapeutics by 44.4% during the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after buying an additional 3,120 shares during the period. Finally, Sciencast Management LP bought a new position in Amicus Therapeutics during the fourth quarter valued at $100,000.

Amicus Therapeutics Trading Down 6.3 %

Shares of NASDAQ FOLD opened at $7.50 on Friday. Amicus Therapeutics, Inc. has a 1-year low of $7.39 and a 1-year high of $12.65. The business has a fifty day moving average price of $9.12 and a 200 day moving average price of $9.86. The stock has a market capitalization of $2.30 billion, a P/E ratio of -41.67, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42.

Analyst Upgrades and Downgrades

FOLD has been the subject of a number of recent analyst reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. StockNews.com downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, February 20th. Cantor Fitzgerald restated an "overweight" rating and set a $21.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Wells Fargo & Company reduced their target price on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, February 20th. Finally, Morgan Stanley reissued an "equal weight" rating and set a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $16.75.

Remove Ads

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.